Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226821 · ClinicalTrials.gov registry record · Phase 4
Body Composition and Adipose Tissue in HIV
A Phase 4 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03226821 is a Phase 4 study that was terminated before completion, run by Columbia University. The registered enrollment target is 6 participants.
The verdict
NCT03226821, a Phase 4 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.
Interventions
- DRUG Tesamorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226821
The ClinicalTrials.gov registry entry for NCT03226821 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tesamorelin is the first listed.
NCT03226821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03226821 about?
NCT03226821 is a clinical study titled "Body Composition and Adipose Tissue in HIV". In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with H...
What is the current status of trial NCT03226821?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-02-07. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT03226821?
The interventions under investigation include: Tesamorelin (DRUG).
Who is sponsoring clinical trial NCT03226821?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.